Abstract: Methods for preparation of isoindolin-1-one compounds are described.

Abstract: Methods for preparation of isoindolin-1-one compounds are described.

Abstract: The present invention provides processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones which are useful, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-?. The invention can provide cost-effective and efficient processes for the commercial production of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones, including, but not limited to, 4-[(N,N-dimethylhydrazono)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, 4-aminomethyl-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione, and 4-[(acylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-diones.

Abstract: The present invention provides new processes for the preparation of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds which are usefuil, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-?. The invention can provide improved and/or efficient processes for the commercial production of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds, including, but not limited to, unsubstituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.

Abstract: The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.

Abstract: The present invention concerns new processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines which are useful for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF?. The invention provides processes for the commercial production of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines including, but not limited to, the therapeutically active 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

Abstract: An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.

Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.